<DOC>
	<DOCNO>NCT02226289</DOCNO>
	<brief_summary>Bevacizumab , humanize monoclonal antibody vascular endothelial growth factor ( VEGF ) , combine fluoropyrimidine-based chemotherapy standard first second-line treatment metastatic colorectal cancer . The efficacy bevacizumab cytotoxic agent third-line treatment patient mCRC still unknown .</brief_summary>
	<brief_title>Bevacizumab-containing Regimen Metastatic Colorectal Cancer Failed Cytotoxic Treatment</brief_title>
	<detailed_description>This single arm , phase II , open-labelled clinical trial evaluate safety efficacy bevacizumab combine cytotoxic agent treatment patient mCRC progress available cytotoxic chemotherapy</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed informed consent obtain . Subjects must able understand willing sign write informed consent . Subjects &gt; 18 year age Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Histological cytological diagnosis adenocarcinoma colon rectum . Subjects unresectable metastatic lesion . Subjects fail respond oxaliplatin , irinotecan fluorouracil . Subjects least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion measure within 4 week prior registration . Leukocytes ≥ 3.0 x109/ L , absolute neutrophil count ( ANC ) ≥ 1.5 x109/ L , platelet count ≥ 100 x109/ L , hemoglobin ( Hb ) ≥ 9g/ dL . Total bilirubin ≤1.5 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 5 x ULN . Amylase lipase ≤ 1.5 x ULN . Serum creatinine ≤ 1.5 x ULN . Calculated creatinine clearance 24 hour creatinine clearance ≥ 50 mL/ min . Any previous concurrent cancer distinct primary site histology colorectal cancer within 5 year prior study . Extended field radiotherapy within 4 week limited field radiotherapy within 2 week prior randomization . Major surgical procedure , open biopsy , significant traumatic injury within 4 week start study medication . Uncontrolled hypertension . ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) . Significant cardiovascular disease include unstable angina myocardial infarction within 6 month initiate study treatment history ventricular arrhythmia Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication . Any evidence active infection . Known history human immunodeficiency virus ( HIV ) infection . History bleed diathesis coagulopathy . History interstitial pneumonitis pulmonary fibrosis Pregnancy lactation time study entry . Any history currently know brain metastasis . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Any illness medical condition unstable could jeopardize safety subject his/her compliance study . Subjects know allergy study drug excipients . Current recent ( within 4 week prior start study treatment ) treatment another investigational drug participation another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>refractory</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>